Clinical Trials Logo

PDGFR-Alpha D842V clinical trials

View clinical trials related to PDGFR-Alpha D842V.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT03620318 Available - FLT3-ITD Mutation Clinical Trials

Individual Patient Compassionate Use of Crenolanib

Start date: n/a
Phase:
Study type: Expanded Access

Compassionate use of crenolanib for patients with serious life-threatening illness that have exhausted all available therapies used to treat the disease, with no other viable therapy options, who is not eligible for clinical trials. This program is designed to evaluate the requests on a patient by patient basis. Patients must have documented evidence of a point mutation in position 842 in platelet derived growth factor receptor alpha (PDGFRA-D842V) or amplification of PDGFRA or internal tandem duplication within the FMS-like tyrosine kinase 3 (FLT3-ITD) or point mutations within the tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD)